Please select an option below to help us tailor your newsletter to best suit your content interests!
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 3
Open to Enrollment
1st Line
Saruparib
PARP inhibitor
Brad Somer, MD
AstraZeneca
Adenocarcinoma
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate Cancer
Stage 4
Phase 3
Open to Enrollment
2nd Line Hormonal Therapy
MK-5684
CYP11A1 inhibitor
Brad Somer, MD
Merck Sharp and Dohme
Castration-Resistant
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
> or - 2nd line
Pembrolizumab, Lenvatinib
PD-1 inhibitor, VEG-F TKI
Dan Vaena, MD
Merck Sharp and Dohme
Prostate Adenocarcinoma without small cell histology
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
1st or later
Pemrbolizumab and Lenvatinib
PD-1 inhibitor, VEGF TKI
Dan Vaena, MD
Merck Sharp and Dohme
Neuroendocrine castration resistant prostate cancer
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
2nd line or greater
Pembrolizumab Vibostolimab coformulation
PD-1 inhibitor + Anti-TIGIT
Dan Vaena, MD
Merck Sharp and Dohme
Adenocarcinoma
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
Treated or de novo
Pembrolizumab, Carboplatin, Etoposide or Carbo/Etoposide alone
PD-1 inhibitor, chemo
Dan Vaena, MD
Merck Sharp and Dohme
Prostate cancer with neuroendocrine features
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
VIEW TRIAL ON CLINICALTRIALS.GOVProstate
Stage 4
Phase 2
Open to Enrollment
1st Line chemo or later
Pembrolizumab/Vibostolimab
PD-1/anti-TIGIT coformulation
Dan Vaena, MD
Merck Sharp and Dohme
Prostate Adenocarcinoma without small cell histology
A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients
with Somatic Homologous Recombination Deficient Advanced or Metastatic
Cancer
solid tumors
Stage 4
Phase 2
Open to Enrollment
any
Niraparib and Dostarlimab
PARP inhibitor + IgG4 humanized monoclonal antibody resulting in PDL1/2 inhibition.
Gregory Vidal, MD
West Cancer Center
somatic HRD deficiency
Metastatic, recurrent, or unresectable solid tumor with a pathogenic, or presumed pathogenic, somatic mutation of one of the following homologous recombination deficiency (HRD) gene mutations: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD54L, RAD51D, FANC/BRIP1, FANCI, FANCL, FANCN(PALB2), BARD1, CHEK1, CHEK2, CDK12, or PPP2R2A.
Participant must have adequate organ function, defined as follows:
h. Male participant agrees to use a highly effective method of contraception (see Section 5.4 for a list of acceptable birth control methods) starting with the first dose of study treatment through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.
j. If an appropriate archival tumor tissue sample is not available, patient is willing to undergo a pre-treatment tumor biopsy.
Exclusion Criteria:
Patients with the following malignancies will be excluded:
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
VIEW TRIAL ON CLINICALTRIALS.GOVEsophageal, Gastric, Cervical, clear cell renal cell cancer, RCC, hepatocellular carcinoma, HCC, liver cancer, HNSCC, head and neck cancer, oropharyngeal, larynx, hypopharyngeal, oral cavity, melanoma, urothelial carcinoma, bladder cancer, triple-negative breast cancer, TNBC, non-small cell lung cancer, NSCLC, colon, prostate
Stage 4
Phase 1
Open to Enrollment
>1st line
RO7502175
Anti-CCR8 antibody
Dan Vaena, MD
Genentech, Inc.
Carcinoma